The global dilated cardiomyopathy (DCM) therapeutics market is anticipated to grow with a significant CAGR of 8% during the forecast period. DCM is one of the prevalent causes of heart failure in adult patients and represents the most common diagnosis leading to a heart transplant in children. The advancements in healthcare and the introduction of new modern techniques are reducing the challenges for the treatment of pediatric DCM. In addition to this, better understanding the pathogenesis of pediatric DCM and the development of effective therapies outside of cardiac transplantation is also driving the DCM therapeutics market.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/industry-reports/dilated-cardiomyopathy-dcm-therapeutics-market
Furthermore, stem cell and cell-based therapies are offering an innovative approach to restore cardiac structure and function towards normal in pediatric patients. This is possibly reducing the need for aggressive therapies and cardiac transplantation. Hence, a systematic investigation needs to be done by the medical community which will benefit current and novel treatments for pediatric DCM. For instance, mesenchymal stem cells and cardiac stem cells are found to be the most promising cell types for treating children with dilated cardiomyopathy. Therefore, the increasing research activities for stem cell and cell-based therapies are anticipated to drive the DCM therapeutic market significantly during the forecast period.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/dilated-cardiomyopathy-dcm-therapeutics-market
Moreover, the combination of complementary and alternative medicines as adjunctive therapy is also anticipated to benefit DCM patients. For instance, the combination of conventional medical treatment and oral Chinese herbal medicine is representing exciting adjunctive therapies for the DCM. Several of the effective Chinese drugs pharmaceutics for treating DCM includes Huangqi injection, Qiliqiangxin Capsule, and Shenfu injection. This is also anticipated to drive the DCM therapeutics industry share, especially in the Asia-Pacific region. Some of the key players active in the global DCM therapeutics market include Binance, Bitstamp Ltd., Blockstream Corp. Inc., BlockCypher, Inc., Coinbase UK, Ltd., Luno Pte. Ltd., BitMain Technologies Holding Co., and others. By witnessing the opportunity in the market, multiple companies have been successful to secure funding to increase their R&D activities and product portfolio in the DCM therapeutics market.
Global DCM Therapeutics Market- Segmentation
By Drug Class
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Beta-Blockers
- Aldosterone Antagonists
- Digitalis
- Angiotensin II Receptor blockers
- Anticoagulants
By Therapy Devices
- Implantable Cardioverter-Defibrillators (ICDs)
- Biventricular Pacemakers
Heart Pumps
